Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients with Metastatic Triple-Negative Breast Cancer: A Phase 1 Study

JAMA Oncology

Volumn 5, Issue 1, 2019, Pages 74-82

  Emens, Leisha A ^a,b   Cruz, Cristina ^c   Eder, Joseph Paul ^d   Braiteh, Fadi ^e   Chung, Cathie ^f   Tolaney, Sara M ^g   Kuter, Irene ^h   Nanda, Rita ⁱ   Cassier, Philippe A ^j   Delord, Jean Pierre ^k   Gordon, Michael S ^l   Elgabry, Ehab ^m   Chang, Ching Wei ⁿ   Sarkar, Indrani ^o   Grossman, William ^n,o   O'Hear, Carol ⁿ   Fassò, Marcella ⁿ   Molinero, Luciana ⁿ   Schmid, Peter ^p  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d YALE CANCER CENTER   (United States)

^e UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^f Angeles Clinic and Research Institute   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j CENTRE LÉON BÉRARD   (France)

^k INSTITUT CLAUDIUS REGAUD   (France)

^l HonorHealth and the Scottsdale Lincoln Health Network   (United States)

^m F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁿ GENENTECH INC   (United States)

^o With Bellicum Pharmaceuticals Inc   (United States)

^p QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; CD163 ANTIGEN; CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL OUTCOME; COHORT ANALYSIS; DENDRITIC CELL; DIARRHEA; DISEASE BURDEN; DRUG SAFETY; DRUG TOLERABILITY; DURATION OF RESPONSE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GRANULOCYTE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LICHEN PLANUS; LYMPHOCYTE; MACROPHAGE; MAJOR CLINICAL STUDY; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OBJECTIVE RESPONSE RATE; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; PULMONARY HYPERTENSION; RASH; TRIPLE NEGATIVE BREAST CANCER; CLINICAL TRIAL; DISEASE EXACERBATION; EUROPE; IMMUNOLOGY; METASTASIS; MORTALITY; PATHOLOGY; TIME FACTOR; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; DISEASE PROGRESSION; EUROPE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGRESSION-FREE SURVIVAL; TIME FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS; UNITED STATES;

EID: 85053667882     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2018.4224     Document Type: Article

References (37)

1. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011; 16 (suppl 1): 1-11. doi: 10.1634/theoncologist.2011-S1-01 21278435
2. Aysola K, Desai A, Welch C, Triple negative breast cancer-an overview. Hereditary Genet. 2013; 2013 (suppl 2): 001. 25285241
3. Li X, Yang J, Peng L, Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017; 161 (2): 279-287. doi: 10.1007/s10549-016-4059-6 27888421
4. den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017; 161 (3): 549-556. doi: 10.1007/s10549-016-4080-9 28000014
5. Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015; 12 (2): 106-116. doi: 10.7497/j.issn.2095-3941.2015.0030 26175926
6. Adams S, Gray RJ, Demaria S, Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32 (27): 2959-2966. doi: 10.1200/JCO.2013.55.0491 25071121
7. Loi S, Michiels S, Salgado R, Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25 (8): 1544-1550. doi: 10.1093/annonc/mdu112 24608200
8. Denkert C, von Minckwitz G, Brase JC, Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015; 33 (9): 983-991. doi: 10.1200/JCO.2014.58.1967 25534375
9. Gatalica Z, Snyder C, Maney T, Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014; 23 (12): 2965-2970. doi: 10.1158/1055-9965.EPI-14-0654 25392179
10. Mittendorf EA, Philips AV, Meric-Bernstam F, PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014; 2 (4): 361-370. doi: 10.1158/2326-6066.CIR-13-0127 24764583
11. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8 (6): 467-477. doi: 10.1038/nri2326 18500231
12. Muenst S, Schaerli AR, Gao F, Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014; 146 (1): 15-24. doi: 10.1007/s10549-014-2988-5 24842267
13. Herbst RS, Soria JC, Kowanetz M, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515 (7528): 563-567. doi: 10.1038/nature14011 25428504
14. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39 (1): 1-10. doi: 10.1016/j.immuni.2013.07.012 23890059
15. Tecentriq (atezolizumab) [product insert]. South San Francisco, CA: Genentech, Inc; 2018.
16. McDermott DF, Sosman JA, Sznol M, Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016; 34 (8): 833-842. doi: 10.1200/JCO.2015.63.7421 26755520
17. Fehrenbacher L, Spira A, Ballinger M,; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387 (10030): 1837-1846. doi: 10.1016/S0140-6736(16)00587-0 26970723
18. Rittmeyer A, Barlesi F, Waterkamp D,; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389 (10066): 255-265. doi: 10.1016/S0140-6736(16)32517-X 27979383
19. Rosenberg JE, Hoffman-Censits J, Powles T, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387 (10031): 1909-1920. doi: 10.1016/S0140-6736(16)00561-4 26952546
20. Balar AV, Galsky MD Rosenberg JE,; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017; 389 (10064): 67-76. doi: 10.1016/S0140-6736(16)32455-2 27939400
21. Eisenhauer EA, Therasse P, Bogaerts J, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45 (2): 228-247. doi: 10.1016/j.ejca.2008.10.026 19097774
22. Wolchok JD, Hoos A, O'Day S, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15 (23): 7412-7420. doi: 10.1158/1078-0432.CCR-09-1624 19934295
23. Weide B, Martens A, Hassel JC, Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016; 22 (22): 5487-5496. doi: 10.1158/1078-0432.CCR-16-0127 27185375
24. Tumeh PC, Hellmann MD Hamid O, Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017; 5 (5): 417-424. doi: 10.1158/2326-6066.CIR-16-0325 28411193
25. Petrylak DP, Powles T, Bellmunt J, Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study. JAMA Oncol. 2018; 4 (4): 537-544. doi: 10.1001/jamaoncol.2017.5440 29423515
26. Nanda R, Chow LQ, Dees EC, Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016; 34 (21): 2460-2467. doi: 10.1200/JCO.2015.64.8931 27138582
27. Adams S, Schmid P, Rugo HS, Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. J Clin Oncol. 2017; 35 (suppl): abstr 1008.
28. Dirix LY, Takacs I, Jerusalem G, Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018; 167 (3): 671-686. doi: 10.1007/s10549-017-4537-5 29063313
29. Robson M, Im SA, Senkus E, Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017; 377 (6): 523-533. doi: 10.1056/NEJMoa1706450 28578601
30. Lynparza (olaparib) [summary of product characteristics]. Södertälje, Sweden: AstraZeneca; 2014.
31. Tolaney S, Kalinsky K, Kaklamani V, Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas.
32. Vinayak S, Tolaney SM, Schwartzberg LS, TOPACIO/Keynote-162: niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. J Clin Oncol. 2018; 36 (15 suppl): 1011.
33. Domchek SM, Postel-Vinay S, Bang Y, An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC). Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas.
34. Kok M, Voorwerk L, Horlings H, Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): final response data stage I and first translational data. J Clin Oncol. 2018; 36 (15 suppl): 1012.
35. Loibl S, Untch M, Burchardi N, Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J Clin Oncol. 2018; 36 (15 suppl): 3062.
36. Nanda R, Liu MC, Yau C, Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. J Clin Oncol. 2017; 35 (15 suppl): 506. 28029304
37. Pohlmann PR, Diamond JR, Hamilton EP, Atezolizumab + nab-paclitaxel in metastatic triple-negative breast cancer: 2-year update from a phase Ib trial. Poster presented at: 2018 American Association for Cancer Research Annual Meeting; April 14-18, 2018; Chicago, Illinois.